NCT04185363 Phase 3 Completed
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-04-23 Actual
Enrollment · participants 84 Actual
Source updated 2026-06-23 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-05-18 · 2 fields changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study
+ Updated value measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count Recorded edit − Previous value count: 90; type: ACTUAL
+ Updated value count: 84; type: ACTUAL
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial